TY  - JOUR
AU  - Suručić, Relja
AU  - Jevtić, Ivana
AU  - Stanojković, Tatjana
AU  - Popović-Đorđević, Jelena
PY  - 2023
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/7215
AB  - With the increasing global burden of diabetes mellitus type 2, the search for the new drugs, with better pharmacological profile is continued. As a part of this surge, the synthesis, pharmacological in vitro and computational evaluation of five, simple carbamate derivatives, against carbohydrate digestive enzyme α-glucosidase, is disclosed herein. Results of the experimental and computational assessment indicated that examined carbamates deterred the activity of α-glucosidase with acceptable IC50 values ranging from 65.34 to 79.89 μM compared to a standard drug acarbose (109.71 μM). Similarly, the studied compounds displayed in silico binding affinity for α-glucosidase enzyme with significant binding energies. Preliminary toxicity profiles of studied carbamates against three cancerous cell lines indicated their poor activity, suggesting that significant structural modifications have to be made to improve their anticancer efficiency. Results of the present study indicate that the examined carbamates were able to virtually or experimentally interact with an important target of diabetes mellitus type 2. Additionally, a new pharmacophore model is proposed featuring hydrogen bond donating carbamate –NH group, hydrogen bond accepting carbamate –OCH3 group and hydrophobic stabilization of aromatic moieties.
AB  - Са порастом појаве дијабетеса типа 2 у свету, јавља се потрага за новим лековима са што ефикаснијим фармаколошким профилом. Као део овог истраживања, приказана је синтеза, фармаколошко in vitro и рачунарско испитивање пет карбамата једноставне структуре, као инхибитора – глукозидазе, ензима који учествује у дигестивном разлагању шећера. Резултати експерименталног испитивања показали су да испитивани карбамати инхибирају активност – глукозидазе са задовољавајућим IC50 вредностима у опсегу од 65,34 до 79,89 μM, а у поређењу са стандардним леком, акарбозом (109,71  μM). Такође, in silico методом добијене су значајне енергије везивања за активно место –  глукозидазе. У прелиминарном испитивању цитотксичности према три типа канцерозних ћелија, карбамати су показали лошу активност, сугеришући да су потребне значајне структурне промене за побољшање њиховог антиканцерозног дејства. Уопштено говорећи, резултати ове студије показали су да су испитивани карбамати успешно виртуелно и експериментално интераговали са важном метом код дијабетеса типа 2. Такође је предложен и нови фармакофорни модел за -глукозидазу, који укључује карбаматну –NH групу као донора водоничне везе, затим карбаматну –OCH3 групу као акцептора водоничне везе, а такође и стабилизујуће хидрофобне интеракције ароматичних прстенова.
PB  - Belgrade : Serbian Chemical Society
T2  - Journal of the Serbian Chemical Society
T1  - Antidiabetic potential of simple carbamate derivatives: Comparative experimental and computational study
T1  - Антидијабетски потенцијал једноставних карбамата: компаративна експериментална и рачунарска студија
VL  - 88
IS  - 11
SP  - 1089
EP  - 1102
DO  - 10.2298/JSC220923058S
ER  - 

@article{
author = "Suručić, Relja and Jevtić, Ivana and Stanojković, Tatjana and Popović-Đorđević, Jelena",
year = "2023",
abstract = "With the increasing global burden of diabetes mellitus type 2, the search for the new drugs, with better pharmacological profile is continued. As a part of this surge, the synthesis, pharmacological in vitro and computational evaluation of five, simple carbamate derivatives, against carbohydrate digestive enzyme α-glucosidase, is disclosed herein. Results of the experimental and computational assessment indicated that examined carbamates deterred the activity of α-glucosidase with acceptable IC50 values ranging from 65.34 to 79.89 μM compared to a standard drug acarbose (109.71 μM). Similarly, the studied compounds displayed in silico binding affinity for α-glucosidase enzyme with significant binding energies. Preliminary toxicity profiles of studied carbamates against three cancerous cell lines indicated their poor activity, suggesting that significant structural modifications have to be made to improve their anticancer efficiency. Results of the present study indicate that the examined carbamates were able to virtually or experimentally interact with an important target of diabetes mellitus type 2. Additionally, a new pharmacophore model is proposed featuring hydrogen bond donating carbamate –NH group, hydrogen bond accepting carbamate –OCH3 group and hydrophobic stabilization of aromatic moieties., Са порастом појаве дијабетеса типа 2 у свету, јавља се потрага за новим лековима са што ефикаснијим фармаколошким профилом. Као део овог истраживања, приказана је синтеза, фармаколошко in vitro и рачунарско испитивање пет карбамата једноставне структуре, као инхибитора – глукозидазе, ензима који учествује у дигестивном разлагању шећера. Резултати експерименталног испитивања показали су да испитивани карбамати инхибирају активност – глукозидазе са задовољавајућим IC50 вредностима у опсегу од 65,34 до 79,89 μM, а у поређењу са стандардним леком, акарбозом (109,71  μM). Такође, in silico методом добијене су значајне енергије везивања за активно место –  глукозидазе. У прелиминарном испитивању цитотксичности према три типа канцерозних ћелија, карбамати су показали лошу активност, сугеришући да су потребне значајне структурне промене за побољшање њиховог антиканцерозног дејства. Уопштено говорећи, резултати ове студије показали су да су испитивани карбамати успешно виртуелно и експериментално интераговали са важном метом код дијабетеса типа 2. Такође је предложен и нови фармакофорни модел за -глукозидазу, који укључује карбаматну –NH групу као донора водоничне везе, затим карбаматну –OCH3 групу као акцептора водоничне везе, а такође и стабилизујуће хидрофобне интеракције ароматичних прстенова.",
publisher = "Belgrade : Serbian Chemical Society",
journal = "Journal of the Serbian Chemical Society",
title = "Antidiabetic potential of simple carbamate derivatives: Comparative experimental and computational study, Антидијабетски потенцијал једноставних карбамата: компаративна експериментална и рачунарска студија",
volume = "88",
number = "11",
pages = "1089-1102",
doi = "10.2298/JSC220923058S"
}

Suručić, R., Jevtić, I., Stanojković, T.,& Popović-Đorđević, J.. (2023). Antidiabetic potential of simple carbamate derivatives: Comparative experimental and computational study. in Journal of the Serbian Chemical Society
Belgrade : Serbian Chemical Society., 88(11), 1089-1102.
https://doi.org/10.2298/JSC220923058S

Suručić R, Jevtić I, Stanojković T, Popović-Đorđević J. Antidiabetic potential of simple carbamate derivatives: Comparative experimental and computational study. in Journal of the Serbian Chemical Society. 2023;88(11):1089-1102.
doi:10.2298/JSC220923058S .

Suručić, Relja, Jevtić, Ivana, Stanojković, Tatjana, Popović-Đorđević, Jelena, "Antidiabetic potential of simple carbamate derivatives: Comparative experimental and computational study" in Journal of the Serbian Chemical Society, 88, no. 11 (2023):1089-1102,
https://doi.org/10.2298/JSC220923058S . .

TY  - JOUR
AU  - Krunić, Mihajlo
AU  - Penjišević, Jelena
AU  - Suručić, Relja
AU  - Šegan, Sandra
AU  - Kostić-Rajačić, Slađana
AU  - Jevtić, Ivana
PY  - 2023
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/5634
AB  - Fourteen novel N-benzylpiperidine and N,N-diarylpiperazine conjugates were synthesized and pharmacologically evaluated as donepezil analogs, in a ligand-based drug design approach. All compounds possessed high to moderate in vitro inhibitory activity with IC50 in range 2.3–20 µM and selectivity towards acetylcholinesterase, while being inactive towards butyrylcholinesterase. Structure-activity relationship analysis revealed the influence of N,N-diarylpiperazine moiety and the linker connecting two pharmacophores on the inhibitory activity. Kinetic studies on the two most active compounds 7g and 8g (IC50 = 2.3 and 4 µM, respectively) revealed mixed type mode of inhibition, binding to both, free enzyme and enzyme-substrate complex. For further understanding of mechanism of action and binding orientations, molecular docking was performed for all compounds, while the ligand transport simulation and molecular dynamics simulations were performed for 7g and 8g. Computational results corroborated well with in vitro activities and kinetic studies.
PB  - Elsevier B.V.
T2  - Journal of Molecular Structure
T1  - Structure-activity and binding orientations analysis of potent, newly synthesized, acetylcholinesterase inhibitors
VL  - 1276
SP  - 134809
DO  - 10.1016/j.molstruc.2022.134809
ER  - 

@article{
author = "Krunić, Mihajlo and Penjišević, Jelena and Suručić, Relja and Šegan, Sandra and Kostić-Rajačić, Slađana and Jevtić, Ivana",
year = "2023",
abstract = "Fourteen novel N-benzylpiperidine and N,N-diarylpiperazine conjugates were synthesized and pharmacologically evaluated as donepezil analogs, in a ligand-based drug design approach. All compounds possessed high to moderate in vitro inhibitory activity with IC50 in range 2.3–20 µM and selectivity towards acetylcholinesterase, while being inactive towards butyrylcholinesterase. Structure-activity relationship analysis revealed the influence of N,N-diarylpiperazine moiety and the linker connecting two pharmacophores on the inhibitory activity. Kinetic studies on the two most active compounds 7g and 8g (IC50 = 2.3 and 4 µM, respectively) revealed mixed type mode of inhibition, binding to both, free enzyme and enzyme-substrate complex. For further understanding of mechanism of action and binding orientations, molecular docking was performed for all compounds, while the ligand transport simulation and molecular dynamics simulations were performed for 7g and 8g. Computational results corroborated well with in vitro activities and kinetic studies.",
publisher = "Elsevier B.V.",
journal = "Journal of Molecular Structure",
title = "Structure-activity and binding orientations analysis of potent, newly synthesized, acetylcholinesterase inhibitors",
volume = "1276",
pages = "134809",
doi = "10.1016/j.molstruc.2022.134809"
}

Krunić, M., Penjišević, J., Suručić, R., Šegan, S., Kostić-Rajačić, S.,& Jevtić, I.. (2023). Structure-activity and binding orientations analysis of potent, newly synthesized, acetylcholinesterase inhibitors. in Journal of Molecular Structure
Elsevier B.V.., 1276, 134809.
https://doi.org/10.1016/j.molstruc.2022.134809

Krunić M, Penjišević J, Suručić R, Šegan S, Kostić-Rajačić S, Jevtić I. Structure-activity and binding orientations analysis of potent, newly synthesized, acetylcholinesterase inhibitors. in Journal of Molecular Structure. 2023;1276:134809.
doi:10.1016/j.molstruc.2022.134809 .

Krunić, Mihajlo, Penjišević, Jelena, Suručić, Relja, Šegan, Sandra, Kostić-Rajačić, Slađana, Jevtić, Ivana, "Structure-activity and binding orientations analysis of potent, newly synthesized, acetylcholinesterase inhibitors" in Journal of Molecular Structure, 1276 (2023):134809,
https://doi.org/10.1016/j.molstruc.2022.134809 . .

TY  - JOUR
AU  - Penjišević, Jelena
AU  - Šukalović, Vladimir
AU  - Andrić, Deana
AU  - Suručić, Relja
AU  - Kostić Rajačić, Slađana
PY  - 2022
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/5229
AB  - Adrenergic receptors are among the most studied G protein-coupled receptors. Activation or blockade of these receptors is a major therapeutic approach for the treatment of numerous disorders such as cardiac hypertrophy, congestive heart failure, hypertension, angina pectoris, cardiac arrhythmias, depression, benign prostate hyperplasia, anaphylaxis, asthma, and hyperthyroidism. Among all nine cloned adrenoceptor subtypes and the subsequent development of animal models, a significant target for various neurological conditions treatment is alpha1-adrenergic receptors. 2-{[4-(2-Methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles, their 5 substituted derivatives, and structurally similar, arylpiperazine based alpha1-adrenergic receptors antagonists (trazodone, naftopidil, and urapidil) have been subjects of comparative analysis. Most of the novel compounds showed alpha1-adrenergic affinity in the range from 22 nM to 250 nM. The in silico docking and molecular dynamics simulations, binding data together with absorption, distribution, metabolism, and excretion (ADME) calculations identified the promising lead compounds. The results brought out the conclusions which allowed us to propose a rationale for the activity of these molecules and to highlight six compounds (2-5, 8, and 12) that exhibited an acceptable pharmacokinetic profile to the advanced investigation as the potential alpha1-adrenergic receptor antagonists.
PB  - Springer
T2  - Applied Biochemistry and Biotechnology
T1  - The Therapeutic Potential of 2-{[4-(2-methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles as Ligands for Alpha1-Adrenergic Receptor - Comparative In Silico and In Vitro Study
VL  - 194
SP  - 3749
EP  - 3764
DO  - 10.1007/s12010-022-03922-8
ER  - 

@article{
author = "Penjišević, Jelena and Šukalović, Vladimir and Andrić, Deana and Suručić, Relja and Kostić Rajačić, Slađana",
year = "2022",
abstract = "Adrenergic receptors are among the most studied G protein-coupled receptors. Activation or blockade of these receptors is a major therapeutic approach for the treatment of numerous disorders such as cardiac hypertrophy, congestive heart failure, hypertension, angina pectoris, cardiac arrhythmias, depression, benign prostate hyperplasia, anaphylaxis, asthma, and hyperthyroidism. Among all nine cloned adrenoceptor subtypes and the subsequent development of animal models, a significant target for various neurological conditions treatment is alpha1-adrenergic receptors. 2-{[4-(2-Methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles, their 5 substituted derivatives, and structurally similar, arylpiperazine based alpha1-adrenergic receptors antagonists (trazodone, naftopidil, and urapidil) have been subjects of comparative analysis. Most of the novel compounds showed alpha1-adrenergic affinity in the range from 22 nM to 250 nM. The in silico docking and molecular dynamics simulations, binding data together with absorption, distribution, metabolism, and excretion (ADME) calculations identified the promising lead compounds. The results brought out the conclusions which allowed us to propose a rationale for the activity of these molecules and to highlight six compounds (2-5, 8, and 12) that exhibited an acceptable pharmacokinetic profile to the advanced investigation as the potential alpha1-adrenergic receptor antagonists.",
publisher = "Springer",
journal = "Applied Biochemistry and Biotechnology",
title = "The Therapeutic Potential of 2-{[4-(2-methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles as Ligands for Alpha1-Adrenergic Receptor - Comparative In Silico and In Vitro Study",
volume = "194",
pages = "3749-3764",
doi = "10.1007/s12010-022-03922-8"
}

Penjišević, J., Šukalović, V., Andrić, D., Suručić, R.,& Kostić Rajačić, S.. (2022). The Therapeutic Potential of 2-{[4-(2-methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles as Ligands for Alpha1-Adrenergic Receptor - Comparative In Silico and In Vitro Study. in Applied Biochemistry and Biotechnology
Springer., 194, 3749-3764.
https://doi.org/10.1007/s12010-022-03922-8

Penjišević J, Šukalović V, Andrić D, Suručić R, Kostić Rajačić S. The Therapeutic Potential of 2-{[4-(2-methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles as Ligands for Alpha1-Adrenergic Receptor - Comparative In Silico and In Vitro Study. in Applied Biochemistry and Biotechnology. 2022;194:3749-3764.
doi:10.1007/s12010-022-03922-8 .

Penjišević, Jelena, Šukalović, Vladimir, Andrić, Deana, Suručić, Relja, Kostić Rajačić, Slađana, "The Therapeutic Potential of 2-{[4-(2-methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles as Ligands for Alpha1-Adrenergic Receptor - Comparative In Silico and In Vitro Study" in Applied Biochemistry and Biotechnology, 194 (2022):3749-3764,
https://doi.org/10.1007/s12010-022-03922-8 . .